A cell membrane modification technique using domain 4 of intermedilysin for immunotherapy against cancer.

Rapid cell membrane modification techniques are currently being sought in order to develop gene therapy and cellular immunotherapy modalities against cancer and other diseases. We developed a novel technique using the non-toxic portion of intermedilysin, a streptolysin O family cytolysin with a high affinity for human cell membranes, as a cell membrane adaptor module. Domain 4 recombinants of intermedilysin with linker sites at the N-terminus were designed.